Human genetics and malaria: Relevance for the design of clinical trials

Journal of Infectious Diseases

Volumn 198, Issue 9, 2008, Pages 1255-1257

  Parikh, Sunil ^a,b   Rosenthal, Philip J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; ANTIMALARIAL AGENT; BETA GLOBIN; CD31 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; ERYTHROCYTE BAND 3 PROTEIN; FANSIDAR; FC RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAMINE; GLYCOPHORIN C; HEMOGLOBIN S; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MALARIA VACCINE; NITRIC OXIDE SYNTHASE; PROGUANIL; TUMOR NECROSIS FACTOR; VALINE;

AMINO ACID SUBSTITUTION; DISEASE ASSOCIATION; DRUG EFFICACY; EDITORIAL; GENE FREQUENCY; GENETIC DIFFERENCE; GENETIC REGULATION; GENETIC VARIABILITY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOGLOBINOPATHY; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INBORN ERROR OF METABOLISM; INCIDENCE; MALARIA; MALARIA FALCIPARUM; MORTALITY; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREVALENCE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; THALASSEMIA; VACCINATION;

CLINICAL TRIALS AS TOPIC; EVOLUTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALARIA, FALCIPARUM; POLYMORPHISM, GENETIC; RESEARCH DESIGN;

EID: 54249099940     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/592223     Document Type: Editorial

References (49)

1. Sabeti PC, Reich DE, Higgins JM, et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 2002; 419:832-7.
2. Tishkoff SA, Varkonyi R, Cahinhinan N, et al. Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance. Science 2001; 293:455-62.
3. Hartl DL. The origin of malaria: mixed messages from genetic diversity. Nat Rev Microbiol 2004; 2:15-22.
4. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434:214-7.
5. Haldane JBS. Disease and evolution. Ric Sci 1949; 19:68-76.
6. Allison AC. Protection afforded by sickle-cell trait against subtertian malarial infection. Br Med J 1954; 4857:290-4.
7. Hill AV, Allsopp CE, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595-600.
8. Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359:1311-2.
9. Williams TN, Mwangi TW, Wambua S, et al. Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis 2005; 192:178-86.
10. May J, Evans JA, Timmann C, et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA 2007; 297: 2220-6.
11. Friedman MJ. Erythrocytic mechanism of sickle cell resistance to malaria. Proc Assoc Am Physicians 1978; 75:1994-7.
12. Pasvol G, Weatherall DJ, Wilson RJ. Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria. Nature 1978; 274:701-3.
13. Cholera R, Brittain NJ, Gillrie MR, et al. Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A 2008; 105:991-6.
14. Crompton P, Traore B, Kayentao K, et al. Sickle cell trait is associated with delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis 2008; 198:1265-75 (in this issue).
15. Moorthy V, Reed Z, Smith PG. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 2007; 25:5115-23.
16. Williams TN, Mwangi TW, Wambua S, et al. Negative epistasis between the malaria-protective effects of α+-thalassemia and the sickle cell trait. Nat Genet 2005; 37:1253-7.
17. Koch O, Awomoyi A, Usen S, et al. IFNGR1 gene promoter polymorphisms and susceptibility to cerebral malaria. J Infect Dis 2002; 185:1684-7.
18. Morahan G, Boutlis CS, Huang D, et al. A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. Genes Immun 2002; 3:414-8.
19. Verra F, Luoni G, Calissano C, et al. IL4-589C/T polymorphism and IgE levels in severe malaria. Acta Trop 2004; 90:205-9.
20. Walley AJ, Aucan C, Kwiatkowski D, Hill AV. Interleukin-1 gene cluster polymorphisms and susceptibility to clinical malaria in a Gambian case-control study. Eur J Hum Genet 2004; 12:132-8.
21. Wilson JN, Rockett K, Jallow M, et al. Analysis of IL10 haplotypic associations with severe malaria. Genes Immun 2005; 6:462-6.
22. Marquet S, Doumbo O, Cabantous S, et al. A functional promoter variant in IL12B predisposes to cerebral malaria. Hum Mol Genet 2008 7:2190-5.
23. Sabeti P, Usen S, Farhadian S, et al. CD40L association with protection from severe malaria. Genes Immun 2002; 3:286-91.
24. Shi YP, Nahlen BL, Kariuki S, et al. Fcγ Receptor IIa (CD32) polymorphism is associated with protection of infants against high-density Plasmodium falciparum infection VII. Asembo Bay Cohort Project. Journal Infect Dis 2001; 184:107-11.
25. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371:508-10.
26. Kun JF, Mordmuller B, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet 1998; 351:265-6.
27. Koch O, Rockett K, Jallow M, Pinder M, Sisay-Joof F, Kwiatkowski D. Investigation of malaria susceptibility determinants in the IFNG/IL26/IL22 genomic region. Genes Immun 2005; 6:312-8.
28. Aucan C, Walley AJ, Hennig BJ, et al. Interferon-α receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia. Genes Immun 2003; 4:275-82.
29. Clark TD, Greenhouse B, Njama-Meya D, et al. Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis 2008; 198:393-400.
30. Lell B, May J, Schmidt-Ott RJ, et al. The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis 1999; 28:794-9.
31. Migot-Nabias F, Mombo LE, Luty AJ, et al. Human genetic factors related to susceptibility to mild malaria in Gabon. Genes Immun 2000; 1:435-41.
32. Parikh S, Dorsey G, Rosenthal PJ. Host polymorphisms and the incidence of malaria in Ugandan children. Am J Trop Med Hyg 2004; 71:750-3.
33. Wambua S, Mwangi TW, Kortok M, et al. The effect of α+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med 2006; 3:e158.
34. Williams TN, Maitland K, Bennett S, et al. High incidence of malaria in α-thalassemic children. Nature 1996; 383:522-5.
35. Flori L, Delahaye NF, Iraqi FA, Hernandez-Valladares M, Fumoux F, Rihet P. TNF as a malaria candidate gene: polymorphism-screening and family-based association analysis of mild malaria attack and parasitemia in Burkina Faso. Genes Immun 2005; 6:472-80.
36. Levesque MC, Hobbs MR, Anstey NM, et al. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. J Infect Dis 1999; 180:1994-2002.
37. Benet A, Khong TY, Ura A, et al. Placental malaria in women with South-East Asian ovalocytosis. Am J Trop Med Hyg 2006; 75: 597-604.
38. Minang JT, Gyan BA, Anchang JK, Troye-Blomberg M, Perlmann H, Achidi EA. Haptoglobin phenotypes and malaria infection in pregnant women at delivery in western Cameroon. Acta Trop 2004; 90:107-14.
39. Mockenhaupt FP, Hamann L, von Gaertner C, et al. Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J Infect Dis 2006; 194:184-8.
40. Kaneko A, Bergqvist Y, Taleo G, Kobayakawa T, Ishizaki T, Bjorkman A. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Pharmacogenetics 1999; 9:317-26.
41. Skjelbo E, Mutabingwa TK, Bygbjerg I, Nielsen KK, Gram LF, Broosen K. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996; 59:304-11.
42. Kaneko A, Kaneko O, Taleo G, Bjorkman A, Kobayakawa T. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 1997; 349:921-2.
43. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007; 82:197-203.
44. Kimman TG, Vandebriel RJ, Hoebee B. Genetic variation in the response to vaccination. Community Genet 2007; 10:201-17.
45. Ayi K, Min-Oo G, Serghides L, et al. Pyruvate kinase deficiency and malaria. N Engl J Med 2008; 358:1805-10.
46. Min-Oo G, Fortin A, Tam MF, Nantel A, Stevenson MM, Gros P. Pyruvate kinase deficiency in mice protects against malaria. Nat Genet 2003; 35:357-62.
47. Sokhna CS, Rogier C, Dieye A, Trape JF. Host factors affecting the delay of reappearance of Plasmodium falciparum after radical treatment among a semi-immune population exposed to intense perennial transmission. Am J Trop Med Hyg 2000; 62:266-70.
48. Mackinnon MJ, Mwangi TW, Snow RW, Marsh K, Williams TN. Heritability of malaria in Africa. PLoS Med 2005; 2:e340.
49. Terlouw DJ, Aidoo MA, Udhayakumar V, et al. Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in Western Kenya. J Infect Dis 2002; 186:1661-8.